Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts.
Lim, Wah-Seng
Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts. [electronic resource] - Leukemia & lymphoma Aug 2010 - 1536-42 p. digital
Publication Type: Journal Article
1029-2403
10.3109/10428194.2010.490312 doi
Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacokinetics
Bone Marrow Cells--drug effects
Chemistry, Pharmaceutical
Cytarabine--administration & dosage
DNA-Binding Proteins--physiology
Daunorubicin--administration & dosage
Dosage Forms
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Synergism
Female
Flow Cytometry
Humans
Liposomes
Maximum Tolerated Dose
Mice
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy
Survival Rate
Tissue Distribution
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts. [electronic resource] - Leukemia & lymphoma Aug 2010 - 1536-42 p. digital
Publication Type: Journal Article
1029-2403
10.3109/10428194.2010.490312 doi
Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacokinetics
Bone Marrow Cells--drug effects
Chemistry, Pharmaceutical
Cytarabine--administration & dosage
DNA-Binding Proteins--physiology
Daunorubicin--administration & dosage
Dosage Forms
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Synergism
Female
Flow Cytometry
Humans
Liposomes
Maximum Tolerated Dose
Mice
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy
Survival Rate
Tissue Distribution
Tumor Cells, Cultured
Xenograft Model Antitumor Assays